Risk of calcium oxalate nephrolithiasis after calcium or combined calcium and calcitriol supplementation in postmenopausal women

• Published in: Osteoporosis international Vol. 11; no. 6; pp. 486 - 492
• Main Authors: DOMRONGKITCHAIPORN, S, ONGPHIPHADHANAKUL, B, STITCHANTRAKUL, W, PIASEU, N, CHANSIRIKARN, S, PUAVILAI, G, RAJATANAVIN, R
• Format: Journal Article
• Language: English
• Published: London Springer 01.07.2000; Springer Nature B.V
• Subjects: Aged; Biological and medical sciences; Calcitriol - adverse effects; Calcium - adverse effects; Calcium - urine; Calcium Oxalate - urine; Citric Acid - urine; Dietary Supplements - adverse effects; Drug toxicity and drugs side effects treatment; Female; Humans; Kidney Calculi - etiology; Magnesium - urine; Medical sciences; Nephrolithiasis; Osteoporosis, Postmenopausal - diet therapy; Pharmacology. Drug treatments; Prospective Studies; Risk Factors; Toxicity: urogenital system; Human; Kidney disease; Urinary system disease; Calcium; Toxicity; Diseases of the osteoarticular system; Calcitriol; Bone disease; Kidney; Urinary stone; Osteoporosis; Chemotherapy; Treatment; Vitamin D; Risk factor; Lithiasis; Postmenopause; Female; Elderly; Colecalciferol
• ISSN: 0937-941X; 1433-2965
• DOI: 10.1007/s001980070090

Although calcium supplementation can cause hypercalciuria, the risk of nephrolithiasis has been shown to decrease rather than increase among subjects who had a higher calcium intake. Hypercalciuria is also a well-established side effect of calcitriol administration. However, the risk of nephrolithiasis is not well defined. The present study was undertaken to prospectively determine the effect of calcium with or without calcitriol on physicochemical risk factors associated with calcium oxalate nephrolithiasis in Thai postmenopausal women with osteoporosis. Subjects consisted of 53 Thai women more than 10 years postmenopausal who were randomly allocated to receive 750 mg of calcium carbonate supplement alone (n = 28) or 750 mg of calcium carbonate plus 0.5 microg calcitriol (n = 25) daily. Mean +/- SEM for age was 65.3+/-1.1 years, body weight 53.5+/-1.3 kg. Urine samples for biochemical assays were collected at baseline and 3 months after treatment. Supersaturation for calcium oxalate stone formation was assessed from the 24 h urine constituents by the Tiselius's index, AP(CaOx). Three months of calcium supplement alone resulted in a modest, but not significant, increase in urinary calcium (baseline, 2.90+/-0.43 mmol/day; after treatment 3.58+/-0.54 mmol/day) with no change in urinary oxalate, citrate or magnesium. In contrast, calcium together with calcitriol caused a significant increase in urinary calcium (baseline, 2.87+/-0.41 mmol/day; after treatment, 4.08+/-0.57 mmol/day; p < 0.05). No significant change in other urine constituents after treatment with calcium and calcitriol was detected. Therefore, AP(CaOx) did not significantly increase either after calcium alone (baseline, 1.17+/-0.39; after treatment, 1.36+/-0.28) or after calcium plus calcitriol (baseline, 1.09+/-0.17; after treatment, 1.09+/-0.19). However, after treatments, 12 subjects (23%)--6 receiving calcium supplement alone and 6 receiving calcium plus calcitriol supplement--had high AP(CaOx) values (greater than the upper limit of 95% Cl for AP(CaOx) derived from non-stone-forming Thai women). The post-treatment/baseline ratio was 3.21+/-0.74 for urinary calcium, 1.01+/-0.19 for urinary oxalate, and 2.23+/-0.42 (median 1.15) for AP(CaOx). The post-treatment/baseline ratio of calcium, but not for urinary oxalate, had a significant correlation with the post-treatment/baseline ratio of AP(CaOx). Our findings suggest that the alteration in the risk of calcium oxalate nephrolithiasis based on urinary composition is related to the alteration in urinary calcium. The risk of calcium oxalate nephrolithiasis does not increase significantly after calcium or combined calcium and calcitriol supplement in the majority of postmenopausal women with osteoporosis.